Jennifer Mak Sells 74 Shares of Axon Enterprise (NASDAQ:AXON) Stock

Axon Enterprise, Inc (NASDAQ:AXON) CAO Jennifer Mak sold 74 shares of the firm’s stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $536.75, for a total value of $39,719.50. Following the completion of the sale, the chief accounting officer directly owned 14,408 shares in the company, valued at approximately $7,733,494. This trade represents a 0.51% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Axon Enterprise Price Performance

Shares of NASDAQ AXON opened at $550.61 on Friday. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.12 and a quick ratio of 2.89. The firm has a market capitalization of $43.45 billion, a PE ratio of 174.24, a P/E/G ratio of 124.84 and a beta of 1.40. Axon Enterprise, Inc has a 1-year low of $469.24 and a 1-year high of $885.91. The business’s fifty day moving average price is $642.45 and its two-hundred day moving average price is $721.62.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 EPS for the quarter, missing the consensus estimate of $1.63 by ($0.46). The firm had revenue of $710.64 million for the quarter, compared to the consensus estimate of $704.83 million. Axon Enterprise had a return on equity of 4.29% and a net margin of 10.05%.The firm’s revenue was up 30.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.45 EPS. On average, research analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Institutional Trading of Axon Enterprise

A number of institutional investors and hedge funds have recently modified their holdings of the company. Westside Investment Management Inc. increased its position in Axon Enterprise by 4.8% during the second quarter. Westside Investment Management Inc. now owns 283 shares of the biotechnology company’s stock worth $225,000 after acquiring an additional 13 shares during the period. CVA Family Office LLC raised its position in Axon Enterprise by 26.9% in the 2nd quarter. CVA Family Office LLC now owns 66 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 14 shares during the last quarter. Newbridge Financial Services Group Inc. grew its holdings in Axon Enterprise by 2.8% during the 2nd quarter. Newbridge Financial Services Group Inc. now owns 508 shares of the biotechnology company’s stock worth $421,000 after acquiring an additional 14 shares during the last quarter. Vicus Capital lifted its holdings in Axon Enterprise by 3.7% during the 3rd quarter. Vicus Capital now owns 396 shares of the biotechnology company’s stock worth $284,000 after buying an additional 14 shares in the last quarter. Finally, Evergreen Capital Management LLC increased its position in Axon Enterprise by 3.8% in the second quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock worth $342,000 after purchasing an additional 15 shares during the period. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

AXON has been the topic of several research analyst reports. Weiss Ratings reissued a “hold (c-)” rating on shares of Axon Enterprise in a research note on Monday. UBS Group lowered their price target on Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 5th. Piper Sandler dropped their price target on shares of Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. JMP Securities restated a “market outperform” rating and set a $825.00 price objective on shares of Axon Enterprise in a research report on Monday, September 29th. Finally, Royal Bank Of Canada initiated coverage on shares of Axon Enterprise in a report on Monday, November 17th. They issued an “outperform” rating and a $860.00 target price on the stock. Fifteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $814.00.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.